Statin Applications in Breast Cancer Management

Statins, originally prescribed for hypercholesterolaemia, inhibit HMG-CoA reductase and limit synthesis of mevalonate pathway intermediates essential for prenylation of oncogenic proteins. This biochemical blockade disrupts growth-promoting signalling cascades, notably Akt, and induces cell-cycle arrest through downregulation of cyclin D1 and upregulation of p27. Preclinical models reveal that lipophilic statins suppress proliferation of primary tumour cells and prevent emergence of dormant micrometastases in liver and lung microenvironments. Observational studies across multiple cohorts report that both pre-diagnostic and post-diagnostic statin use is associated with lower breast cancer-specific mortality, with evidence of greater benefit in oestrogen receptor-negative disease. Variability in outcomes likely reflects differences in statin type, duration of exposure and patient demographics. Emerging work is investigating biomarker signatures to predict statin sensitivity, potential synergy with endocrine therapies or metformin, and impact on tumour immune infiltration. Owing to their widespread availability, well-established safety profile and low cost, statins represent a promising adjunct for long-term adjuvant intervention, although definitive evidence from randomised controlled trials remains awaited.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Statin Applications in Breast Cancer Management publication trend

The graph below shows the total number of articles in statin applications in breast cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

HMG-CoA reductase: The enzyme catalysing the rate-limiting step of cholesterol and isoprenoid synthesis in the mevalonate pathway.

Mevalonate pathway: A metabolic cascade producing cholesterol, dolichol and prenyl groups required for protein isoprenylation and membrane localisation.

Prenylation: A post-translational modification that attaches lipid groups (farnesyl or geranylgeranyl) to proteins, enabling membrane association and signal transduction.

Oestrogen receptor status: A classification of breast tumours based on expression of oestrogen receptors, influencing responsiveness to hormonal therapies.

Cell cycle arrest: The halting of cell division at specific checkpoints, often mediated by regulators such as cyclin D1 and p27, to prevent uncontrolled proliferation.

References

1. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Research (2023).
2. Statin use as a moderator on the association between metformin and breast cancer risk in women with type 2 diabetes mellitus. Cancer & Metabolism (2024).
3. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Journal of Translational Medicine (2015).
4. Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLOS ONE (2018).
5. Statins attenuate outgrowth of breast cancer metastases. British Journal of Cancer (2018).